Evidence map›Paper›PMID 32918791›Full record

Trial reportThe oncologist2021

Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer.

Hidetoshi Hayashi, Masakazu Ogura, Takashi Niwa, Toshihide Yokoyama, Junko Tanizaki, Tomohiro Ozaki, Hiroshige Yoshioka, Takayasu Kurata, Yosuke Tamura, Yasuhito Fujisaka and 5 more

Open access · bronzeAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The oncologist, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 1 country.

Hidetoshi HayashiDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.
Masakazu OguraDepartment of Radiation Oncology, Kishiwada City Hospital, Kishiwada, Japan.
Takashi NiwaDepartment of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan.
Toshihide YokoyamaDepartment of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan.
Junko TanizakiDepartment of Medical Oncology, Kishiwada City Hospital, Kishiwada, Japan.
Tomohiro OzakiDepartment of Medical Oncology, Kishiwada City Hospital, Kishiwada, Japan.
Hiroshige YoshiokaDepartment of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Japan.
Takayasu KurataDepartment of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Japan.
Yosuke TamuraDepartment of Respiratory Medicine and Thoracic Oncology, Osaka Medical College Hospital, Takatsuki, Japan.
Yasuhito FujisakaClinical Research Center, Osaka Medical College Hospital, Takatsuki, Japan.
Kaoru TanakaDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.
Yoshikazu HasegawaDepartment of Medical Oncology, Izumi City General Hospital, Izumi, Japan.
Keita KudoDepartment of Thoracic Medical Oncology, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan.
Yasutaka ChibaClinical Research Center, Kindai University Hospital, Higashiosaka, Japan.
Kazuhiko NakagawaDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.
Kindai University · JPKishiwada City Hospital · JPKansai Medical University · JPKurashiki Central Hospital · JPOsaka Medical and Pharmaceutical University · JPIzumi City General Hospital · JPKindai University Hospital · JPOsaka Minami Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

lessons learnedThe combination of cisplatin plus nab-paclitaxel with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer is a promising therapeutic strategy. Further investigation is warranted.

backgroundWe conducted a phase I/II trial of cisplatin plus nab-paclitaxel with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (NSCLC) to determine the recommended dose (RD) of nab-paclitaxel and to evaluate the safety and efficacy of this regimen.

methodsIn the phase I study, escalating doses of weekly nab-paclitaxel were administered together with cisplatin at 75 mg/m

resultsIn the phase I study, whereas no dose-limiting toxicity (DLT) was observed with nab-paclitaxel at 50 or 60 mg/m

conclusionConcurrent chemoradiation with nab-paclitaxel at 70 mg/m

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAlbuminsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyCisplatinCombined Modality TherapyHumansPaclitaxel130-nm albumin-bound paclitaxelAlbuminsCisplatinPaclitaxelCisplatinDose-limiting toxicitynab-PaclitaxelNon-small cell lung cancerRadiotherapy

Identifiers

PMID32918791
PMCPMC7794196
OpenAlexW3086963827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.